Anderson MA et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood 2017;129(25):3362-70. Abstract

Byrd JC et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 2016;374(4):323-32. Abstract

Chen R et al; KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35(19):2125-32. Abstract

Connors J et al; ECHELON-1 Study Group. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 2018;378(4):331-44. Abstract

Dreyling M et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol 2017;28(9):2169-78. Abstract

Furman R et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370(11):997-1007. Abstract

Hamblin TJ et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94(6):1848-54. Abstract

International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data. Lancet Oncol 2016;17(6):779-90. Abstract

Kipps TJ et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers 2017;3:17008. Abstract

Kovacs G et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: Comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol 2016;34(31):3758-65. Abstract

Lampson BL et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 2016;128(2):195-203. Abstract

Locke FL et al. Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther 2017;25(1):285-95. Abstract

Maddocks KJ et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 2015;1(1):80-7. Abstract

Marcus R et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 2017;377(14):1331-44. Abstract

Moskowitz CH et al; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385(9980):1853-62. Abstract

O’Brien SM et al. Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Proc ASH 2016;Abstract 233.

Rummel M et al. Four versus two years of rituximab maintenance (R-maintenance) following bendamustine plus rituximab (B-R): Initial results of a prospective, randomized multicenter phase 3 study in first-line follicular lymphoma (the StiL NHL7-2008 MAINTAIN study). Proc ASH 2017;Abstract 483.

Schmitz N et al. CNS International Prognostic Index: A risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2016;34(26):3150-6. Abstract

Seymour JF et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: A phase 1b study. Lancet Oncol 2017;18(2):230-40. Abstract

Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: Working toward cure for patients with CLL. Blood 2016;127(3):279-86. Abstract

Thompson PA et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016;127(3):303-9. Abstract

Wierda W et al. Venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion: Outcomes and minimal residual disease (MRD) from the full population of the pivotal M13-982 trial. Proc SOHO 2017;Abstract CLL-102.

Woyach JA et al. BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol 2017;35(13):1437-43. Abstract